Buy & Sell Alcon AG (ALC) – Alcon AG Price Today
Aura AI Summary
Key Stats
- $32.30BMarket Cap
- HealthSector
- -23.73%3M Drawdown
- $35.89BEnterprise Value
- 0.56%Dividend Yield
- 71 daysTypical Hold Time
Alcon AG (ALC) is currently valued at a market capitalization of $32.30B, with an enterprise value of $35.89B. Over the past 52 weeks, Alcon AG has traded between a low of $62.02 and a high of $92.22, highlighting its annual price range. Over the past three months, Alcon AG has recorded a drawdown of -23.73%, reflecting recent price volatility. Alcon AG offers a dividend yield of 0.56%, with the most recent dividend of $0.28 paid on 06 May 26. On average, investors hold Alcon AG for approximately 71 days, indicating typical investor behavior on the platform.
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Most Recent News
Cell and gene therapy CDMO market set to grow at 24% CAGR, reaching $57.1B by 2034.
The cell and gene therapy contract development and manufacturing organization (CDMO) market is projected to grow at a compound annual growth rate (CAGR) of approximately 24% from 2026 to 2034, reaching a market size of $57.1 billion by 2034. Growth i...
Over 100 drugs in clinical trials aim to transform age-related macular degeneration treatment by 2026
DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF ...
Polymeric biomaterials market to hit $267B by 2034, driven by regenerative medicine and healthcare growth.
The global polymeric biomaterials market, valued at $69.55 billion in 2024, is projected to grow at a CAGR of 15.86% to reach $267.25 billion by 2034. Growth is fueled by increasing demand in regenerative medicine, orthopedics, and wound care, with A...